Practice Areas

Zip Co will have to rebrand after losing a challenge to non-bank lender Firstmac’s ‘Zip’ trade mark, with the High Court finding the honest concurrent use is to be judged by the standards of “ordinary, decent people”, not a subjective “Robin Hood” test. 

A judge has tossed an environmental group's bid for judicial review of a minister's approval of plans to build water regulating structures at the Nyah Floodplain in Victoria, saying the approval was contingent on plans to offset effects on the Regent parrot.

Mayne Pharma cannot access invoices from Cosette’s solicitors at Corrs Chambers Westgarth, with a judge saying he was not hopeful that they would help to resolve a costs fight related to litigation over their collapsed $672 million merger.

At the centre of Tuesday night's budget are tax reforms aimed at investment structures, negative gearing, and the capital gains perk that represent the biggest change to the taxation of Australian savings since 1999.

AkzoNobel has lost its bid to add new expert evidence after the conclusion of trial in a dispute with Inpex over allegedly defective anti-corrosive coating used on the $45 billion Ichthys natural gas project.

The centrepiece of Tuesday night's budget are tax reforms aimed at capital gains, negative gearing and investment structures, with the Albanese government spruiking the changes as supporting new housing, while experts say the devil is in the detail.

Addressing for the first time the question of compensation for 'future acts' under the Native Title Act, a judge has ordered Fortescue Metals Group to pay $150 million to compensate the Yinjibarndi people for losses stemming from the mining company's Solomon Hub iron ore project.

Shell’s Australian arm has succeeded in challenging a finding by the ATO that it needed to pay an additional $99 million in capital gains tax after it disposed of its 34.27 per cent holding in Woodside Petroleum.

An appeal by the buyers of a $2.3 million real estate business on the NSW Central Coast has fallen short, with a court finding that their solicitor's knowledge of a security charge was properly imputed to them. 

Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.